Follicular Lymphoma Excellence Forum

Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Choosing Treatment Options and Managing Toxicities for Patients With R/R Follicular Lymphoma

08/18/2023

Carla Casulo , MD;

At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Carla Casulo, MD, summarizes the available treatment options for relapsed/refractory follicular lymphoma and options for managing various treatment-related toxicities.

At the 2023 Great Debates &...

08/18/2023

Oncology

Videos

Epcoritamab Plus Rituximab and Lenalidomide Regimen Demonstrates High Response Rates Among Patients With High-Risk Follicular Lymphoma

07/19/2023

Reid Merryman , MD;

At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.

At the 2023 ASCO meeting, Reid...

07/19/2023

Oncology

Videos

Circulating Tumor DNA and Prediction of Early Progression in Follicular Lymphoma

04/13/2023

Margarita Sánchez-Beato, PhD, discusses the monitoring of circulating tumor DNA to predict response to treatment and early progression among patients with follicular lymphoma.

Margarita Sánchez-Beato, PhD,...

04/13/2023

Oncology

Quiz

Quiz: Triplet Therapy Combination for R/R Follicular Lymphoma

03/23/2023

True or False: The triplet therapy combination of epcoritamab and rituximab and lenalidomide was active in patients with R/R follicular lymphoma, including those who might be more difficult to treat, such as refractory patients and those who...

True or False: The triplet...

03/23/2023

Oncology

Quiz

Quiz: Epcoritamab Plus Rituximab and Lenalidomide Treatment for Relapsed/Refractory Follicular Lymphoma

03/23/2023

True or False: In a study exploring subcutaneous epcoritamab combined with rituximab and lenalidomide treatment for patients with relapsed/refractory follicular lymphoma, the majority of patients who had a partial response at first assessment...

True or False: In a study...

03/23/2023

Oncology

Matthew Matasar, MD, Rutgers Cancer Institute of New Jersey

Videos

Mosunetuzumab Demonstrates Favorable Efficacy and Tolerability in Relapsed/Refractory Follicular Lymphoma

11/16/2022

Matthew Matasar, MD, discusses a phase 2 study assessing the safety and efficacy of fixed-duration mosunetuzumab, a CD20-CD3 T-cell-engaging bispecific monoclonal antibody, for relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, discusses a...

11/16/2022

Oncology

Videos

Subcutaneous Epcoritamab With Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma

11/02/2022

Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.

Lorenzo Falchi, MD, presents...

11/02/2022

Oncology

Sarah Rutherford, MD, Weill Cornell Medicine

Videos

CAR-T Therapy vs Other Novel Agents for Third-Line Treatment of FL

05/22/2022

Sarah Rutherford, MD, debates why she believes CAR-T therapy is the preferred treatment for patients with early progressing FL after 2 lines of prior therapy.

Sarah Rutherford, MD, debates...

05/22/2022

Oncology

Videos

Long-term Safety of Rituximab Biosimilar in Untreated Advanced FL

04/07/2022

Christian Buske, MD, overviews a phase 3 study on the long-term safety and efficacy of CT-P10, a rituximab biosimilar, in patients with untreated advanced FL.

Christian Buske, MD, overviews a...

04/07/2022

Oncology

Carla Casulo, MD, Wilmot Cancer Institute, University of Rochester

Podcasts

Treatment Options for Managing Patients With Newly Diagnosed or Relapsed FL

03/25/2022

Carla Casulo, MD, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed FL.

Carla Casulo, MD, overviews the...

03/25/2022

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology